BIOMARKER:

MYD88 mutation

Entrez ID:

Related biomarkers:

‹

›

MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C2 – Inclusion Criteria	ibrutinib Sensitive: C2 – Inclusion Criteria
MYD88 mutation MYD88 mutation	Marginal Zone Lymphoma Marginal Zone Lymphoma	MYD88 mutation MYD88 mutation	Marginal Zone Lymphoma Marginal Zone Lymphoma	ibrutinib Sensitive: C3 – Early Trials	ibrutinib Sensitive: C3 – Early Trials
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials	ibrutinib Sensitive: C3 – Early Trials
MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab Sensitive: C4 – Case Studies	rituximab Sensitive: C4 – Case Studies
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	BTK inhibitor + KT-413 Sensitive: D – Preclinical	BTK inhibitor + KT-413 Sensitive: D – Preclinical
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab + KT-413 Sensitive: D – Preclinical	rituximab + KT-413 Sensitive: D – Preclinical
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical	KT-413 Sensitive: D – Preclinical